top of page

Jul 21, 2023

PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale

Apr 20, 2023

PsyBio Announces Closing of Third Tranche of Private Placement

Apr 6, 2023

PsyBio Announces Panel Participation on NextGen Psychedelics at Benzinga Cannabis Capital Conference

Mar 13, 2023

PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit

Jan 17, 2023

A PsyBio Therapeutics Corp. (CVE:PSYB) insider increased their holdings last year

Jan 13, 2023

PsyBio Announces Closing of Second Tranche of Private Placement

Jan 10, 2023

PsyBio Announces Appointment of Ian Wisenberg to Board of Directors

Jan 5, 2023

PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update

Dec 8, 2022

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

Dec 6, 2022

PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio

Dec 1, 2022

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

Nov 29, 2022

PsyBio Therapeutics Reports Third Quarter 2022 Financial Results

bottom of page